Metabolomic and genomic prediction of common diseases in 477,706 participants in three national biobanks
Nightingale Health Biobank Collaborative Group, ; Barrett, J. C.; Esko, T.; Fischer, K.; Jostins-Dean, L.; Jousilahti, P.; Julkunen, H.; Jaaskelainen, T.; Kerimov, N.; Kerminen, S.; Kolde, A.; Koskela, H.; Kronberg, J.; Lundgren, S. N.; Lundqvist, A.; Makela, V.; Nybo, K.; Perola, M.; Salomaa, V.; Schut, K.; Soikkeli, M.; Soininen, P.; Tiainen, M.; Tillmann`, T.; Wurtz, P.; Estonian Biobank Research Team,
Show abstract
Identifying individuals at high risk of chronic diseases via easily measured biomarkers could improve public health efforts to prevent avoidable illness and death. Here we present nuclear magnetic resonance blood metabolomics from half a million samples from three national biobanks. We built metabolomic risk scores that identify a high-risk group for each of 12 diseases that cause the most morbidity in high-income countries and show consistent cross-biobank replication of the relative risk of disease for these groups. We show that these metabolomic risk scores are more strongly associated with future disease onset than polygenic scores for most of these diseases. In a subset of 18,000 individuals with metabolomic biomarkers measured at two time points we show that people whose scores change have dramatically different future risk of disease, suggesting that repeat measurements capture the benefits of lifestyle change. We show cross-biobank calibration of our scores. Since metabolomics can be measured from a standard blood sample, we propose such tests can be feasibly implemented today in preventative health programs. One-Sentence SummaryBiomarkers from half a million blood samples identifies people at increased risk of chronic diseases and can be used for early detection today.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A unified framework for estimating country-specific cumulative incidence for 18 diseases stratified by polygenic risk 96%
- Metabolome-wide Mendelian randomization characterizes heterogeneous and shared causal effects of metabolites on human health 95%
- Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities 95%
Similar papers in this journal
- Systematic single-variant and gene-based association testing of 3,700 phenotypes in 281,850 UK Biobank exomes 94%
- Polygenic scores capture genetic modification of the adiposity-cardiometabolic risk factor relationship 94%
- Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.